Base de dados : MEDLINE
Pesquisa : D02.033.100.624.870 [Categoria DeCS]
Referências encontradas : 935 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 94 ir para página                         

  1 / 935 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27987333
[Au] Autor:Ogoyama M; Takahashi H; Kobayashi Y; Usui R; Matsubara S
[Ad] Endereço:Department of Obstetrics and Gynecology, Jichi Medical University, Shimotsuke, Japan.
[Ti] Título:Ritodrine-induced rhabdomyolysis, infantile myotonic dystrophy, and maternal myotonic dystrophy unveiled.
[So] Source:J Obstet Gynaecol Res;43(2):403-407, 2017 Feb.
[Is] ISSN:1447-0756
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:A primiparous pregnant woman in remission of myositis suffered very acute-onset ritodrine-induced rhabdomyolysis. At 29 gestational weeks, ritodrine was administered for threatened preterm labor. Just 3 h later, she complained of severe limb muscle pain, with serum creatinine phosphokinase elevated to 32 019 U/L and myoglobinuria. The muscle pain disappeared immediately after ceasing administration of ritodrine. At 31 weeks, premature rupture of the membranes occurred, necessitating cesarean section, yielding a baby with weak tonus, and the presence of infantile muscle diseases was suspected. Genetic analysis of the infant confirmed myotonic dystrophy (dystrophia myotonica, DM), which prompted us to perform maternal genetic analysis, confirming maternal DM. Ritodrine can induce rhabdomyolysis even in the prodromal phase with a mild phenotype of DM. A literature review suggested that ritodrine-induced rhabdomyolysis may be likely to occur more acutely after ritodrine administration in DM compared with non-DM mothers.
[Mh] Termos MeSH primário: Doenças do Recém-Nascido/induzido quimicamente
Distrofia Miotônica/induzido quimicamente
Complicações na Gravidez/induzido quimicamente
Rabdomiólise/induzido quimicamente
Ritodrina/efeitos adversos
Tocolíticos/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Recém-Nascido
Gravidez
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Tocolytic Agents); I0Q6O6740J (Ritodrine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161218
[St] Status:MEDLINE
[do] DOI:10.1111/jog.13211


  2 / 935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27678101
[Au] Autor:Bafor EE; Rowan EG; Edrada-Ebel R
[Ad] Endereço:1 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland, United Kingdom.
[Ti] Título:Toward Understanding Myometrial Regulation: Metabolomic Investigation Reveals New Pathways of Oxytocin and Ritodrine Activity on the Myometrium.
[So] Source:Reprod Sci;24(5):691-705, 2017 May.
[Is] ISSN:1933-7205
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In recent times, additional pathways involved in the regulation of the myometrium have been suggested. This also holds true for the effect of drugs such as oxytocin (OT) and ß-adrenergic agonists on the myometrium. Knowledge of these additional pathways will certainly prove useful in designing better therapies for pathologies of the myometrium. This study was therefore aimed at investigating the possibility of other pathways involved in the activities of both OT and ritodrine (RIT; a ß-adrenergic agonist) in the myometrium by utilizing metabolomics and bioinformatics. High-resolution Fourier transform mass spectrometry (HRFTMS) and nuclear magnetic resonance (NMR) spectroscopy coupled with functional uterine assays were used for an innovative assessment. In vitro pharmacological assay of OT (1 nmol/L) and RIT (0.1 nmol/L) on isolated mice uteri mounted in 3 mL organ baths was performed. Mice uteri, treated with OT or RIT, as well as the physiological buffer in which the uterine tissues were immersed, were rapidly collected and analyzed using HRFTMS, proton ( H)-NMR, and bioinformatics. Resulting data were analyzed via pairwise chemometric comparison models, with P ≤ .05 considered statistically significant. In addition to previously known metabolites, nicotinamide adenine dinucleotide, γ-aminobutyric acid, and sphingosine were significantly associated with the activity of OT, whereas the activity of RIT was associated with a downstream involvement of prostaglandin F and phosphatidylinositol signaling. These findings add evidence to the reports on additional regulation of myometrial activity by these drugs and suggest newer pathways for therapeutic manipulation.
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem
Miométrio/metabolismo
Ocitocina/metabolismo
Ritodrina/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Biologia Computacional
Feminino
Espectroscopia de Ressonância Magnética/métodos
Espectrometria de Massas/métodos
Metabolômica
Camundongos
Camundongos Endogâmicos C57BL
Miométrio/efeitos dos fármacos
Miométrio/fisiologia
Ocitocina/administração & dosagem
Transdução de Sinais/efeitos dos fármacos
Contração Uterina/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 50-56-6 (Oxytocin); I0Q6O6740J (Ritodrine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170505
[Lr] Data última revisão:
170505
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160929
[St] Status:MEDLINE
[do] DOI:10.1177/1933719116667224


  3 / 935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28040144
[Au] Autor:Teraoka Y; Samura O; Mukai Y; Sasaki M
[Ad] Endereço:Department of Obstetrics and Gynecology, Onomichi General Hospital, Hiroshima, Japan. Electronic address: yteraoka@hiroshima-u.ac.jp.
[Ti] Título:A case of fetomaternal transfusion in trichorionic triamniotic triplets.
[So] Source:Taiwan J Obstet Gynecol;55(6):895-896, 2016 Dec.
[Is] ISSN:1875-6263
[Cp] País de publicação:China (Republic : 1949- )
[La] Idioma:eng
[Mh] Termos MeSH primário: Transfusão Feto-Materna/sangue
Gravidez de Trigêmeos
Trigêmeos
[Mh] Termos MeSH secundário: Adulto
Transfusão de Sangue
Cesárea
Evolução Fatal
Feminino
Frequência Cardíaca Fetal
Seres Humanos
Recém-Nascido
Masculino
Trabalho de Parto Prematuro
Gravidez
Ritodrina/uso terapêutico
Tocolíticos/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Tocolytic Agents); I0Q6O6740J (Ritodrine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170102
[St] Status:MEDLINE


  4 / 935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27751427
[Au] Autor:Wang CY; Lai YJ; Hwang KS; Chen CH; Yu MH; Chen HT; Su HY
[Ad] Endereço:Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
[Ti] Título:Successful treatment with granulocyte-colony stimulating factor for ritodrine-induced neutropenia in a twin pregnancy.
[So] Source:Taiwan J Obstet Gynecol;55(5):738-740, 2016 Oct.
[Is] ISSN:1875-6263
[Cp] País de publicação:China (Republic : 1949- )
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Neutropenia developed after continuous intravenous infusion of ritodrine hydrochloride (Yutopar) for preterm uterine contractions in a twin pregnancy. We successfully returned the low neutrophil count to the normal range after discontinuation of infusion of ritodrine and treatment with granulocyte colony stimulating factor (G-CSF). CASE REPORT: A 34-year-old woman with twin pregnancy was treated with ritodrine for preterm uterine contractions at 27 weeks and 6 days gestation. Neutropenia developed after continuous intravenous infusion of ritodrine for about 4 weeks. We ceased the ritodrine infusion immediately and treated the neutropenia with G-CSF. A cesarean delivery was performed the day after cessation of the ritodrine infusion because of uncontrolled preterm labor. There were no adverse side effects or infectious complications in the mother or the newborns. The maternal neutrophil count recovered to the normal range 4 days after administration of G-CSF. CONCLUSION: Based on prior case reports and the clinical presentation of our case, G-CSF may be a useful treatment for pregnant women with ritodrine-induced neutropenia. However, more clinical studies are required to confirm the safety and efficacy of this treatment.
[Mh] Termos MeSH primário: Fatores Estimuladores de Colônias/farmacologia
Neutropenia/tratamento farmacológico
Gravidez de Gêmeos
Ritodrina/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Cesárea
Feminino
Seres Humanos
Contagem de Leucócitos
Neutropenia/induzido quimicamente
Neutropenia/diagnóstico
Gravidez
Tocolíticos/efeitos adversos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Colony-Stimulating Factors); 0 (Tocolytic Agents); I0Q6O6740J (Ritodrine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170418
[Lr] Data última revisão:
170418
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161019
[St] Status:MEDLINE


  5 / 935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27642169
[Au] Autor:Nakamura M; Hasegawa J; Arakaki T; Hamada S; Takita H; Oba T; Koide K; Matsuoka R; Sekizawa A
[Ad] Endereço:Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan.
[Ti] Título:Comparison of perinatal outcomes between long-term and short-term use of tocolytic agent: a historical cohort study in a single perinatal hospital.
[So] Source:J Obstet Gynaecol Res;42(12):1680-1685, 2016 Dec.
[Is] ISSN:1447-0756
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:AIM: The aim of this study was to evaluate the effect of long-term use of tocolytic agents to prevent preterm delivery and improve perinatal outcome. METHODS: A historical cohort study was performed in a single perinatal center. The maternal characteristics, frequency of preterm labor and prescribed dose of tocolytic agents were compared before and after changing the management protocol for threatened premature delivery. RESULTS: A total of 1548 deliveries were carried out before changing the protocol for the use of tocolytic agents for threatened premature delivery and 1444 deliveries afterwards. There was no significant difference in the maternal characteristics before and after the revision except for maternal age. The total number of ritodrine hydrochloride ampules used was reduced from 4654 to 514, and the total vials of magnesium sulfate used were reduced from 1574 to 193, but perinatal outcomes, such as rate of preterm birth, neonatal weight, and rate of NICU hospitalization were not different between the groups. CONCLUSION: There was no significant change in the frequency of preterm delivery before and after changing of the protocol for threatened premature delivery. Because a decrease in the given dose of tocolytic agents did not affect the timing of delivery and neonatal outcomes, long-term tocolysis in patients with threatened premature delivery should be restricted to prevent maternal and fetal adverse side-effects.
[Mh] Termos MeSH primário: Resultado da Gravidez
Nascimento Prematuro/prevenção & controle
Tocolíticos/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Estudos de Coortes
Feminino
Idade Gestacional
Seres Humanos
Sulfato de Magnésio/administração & dosagem
Sulfato de Magnésio/uso terapêutico
Gravidez
Nascimento Prematuro/tratamento farmacológico
Ritodrina/administração & dosagem
Ritodrina/uso terapêutico
Tocolíticos/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Tocolytic Agents); 7487-88-9 (Magnesium Sulfate); I0Q6O6740J (Ritodrine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160920
[St] Status:MEDLINE
[do] DOI:10.1111/jog.13104


  6 / 935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27348869
[Au] Autor:Kawanishi Y; Saijo Y; Yoshioka E; Nakagi Y; Yoshida T; Miyamoto T; Sengoku K; Ito Y; Miyashita C; Araki A; Kishi R
[Ad] Endereço:Department of Health Science, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
[Ti] Título:The Association between Prenatal Yoga and the Administration of Ritodrine Hydrochloride during Pregnancy: An Adjunct Study of the Japan Environment and Children's Study.
[So] Source:PLoS One;11(6):e0158155, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: While the beneficial effects of prenatal yoga have been reported in recent years, little is known about its effectiveness in pregnant Japanese women. Despite several adverse effects, ritodrine hydrochloride is frequently prescribed to suppress preterm labor in Japan, and its usage may therefore indicate cases of preterm labor. This study aimed to clarify the association between prenatal yoga and ritodrine hydrochloride use during pregnancy. METHODS: An observational study was conducted as an adjunct study by the Hokkaido unit of the Japan Environment and Children's Study. Information on prenatal yoga practice was collected using a self-questionnaire between March 21, 2012, and July 7, 2015, targeting women who had recently delivered. Ritodrine hydrochloride use was identified from medical records. A total of 2,692 women were analyzed using logistic regression models that adjusted for possible confounders. RESULTS: There were 567 (21.1%) women who practiced prenatal yoga, which was associated with a lower risk of ritodrine hydrochloride use (adjusted odds ratio [OR] 0.77; 95% CI 0.61-0.98). This was especially evident in women with a total practice duration that exceeded 900 minutes throughout their pregnancy (adjusted OR 0.54; 95% CI 0.38-0.76). A sensitivity analysis that excluded patients with threatened abortion during the study period produced similar results. CONCLUSIONS: Prenatal yoga was associated with a lower risk of ritodrine hydrochloride use, particularly in women with more than 900 minutes of practice time over the course of their pregnancy. Prenatal yoga may be a beneficial option for pregnant women in the selection of alternative therapies.
[Mh] Termos MeSH primário: Nascimento Prematuro/prevenção & controle
Ritodrina/efeitos adversos
Tocolíticos/efeitos adversos
Ioga
[Mh] Termos MeSH secundário: Adulto
Estudos de Casos e Controles
Feminino
Seres Humanos
Gravidez
Ritodrina/administração & dosagem
Tocolíticos/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Tocolytic Agents); I0Q6O6740J (Ritodrine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160628
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0158155


  7 / 935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26742485
[Au] Autor:Kareli D; Pouliliou S; Liberis A; Nikas I; Psillaki A; Kontomanolis E; Nikolettos N; Galazios G; Lialiaris T
[Ad] Endereço:a Department of Genetics , Laboratory of Genetics, Demokrition University of Thrace , Alexandroupolis , Greece .
[Ti] Título:Genotoxic effect of tocolytic drug ritodrine in combination with smoking during pregnancy.
[So] Source:J Matern Fetal Neonatal Med;29(21):3496-505, 2016 Nov.
[Is] ISSN:1476-4954
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Tocolytic drugs are used widely in order to prevent preterm birth. Ritodrine, is the only food and drug administration (FDA) approved drug for tocolytic use. We estimated the cytogenetic effect of ritodrine administered as maternal therapy, alone or in combination with smoking, in women and their neonates. METHODS: Lymphocyte and fibroblasts cultures were evaluated and three indices were analyzed; sister chromatid exchanges (SCEs), proliferation rate index (PRI) and mitotic index (MI) as well as average generation time (AGT) and population doubling time (PDT). Campothacin (CPT-11) was used as a positive control. RESULTS: Administration of ritodrine up to a month revealed significant reduction of SCEs/cell in neonates in the presence or absence of the mutagenic agent. A statistical significant increase on SCEs, for mothers and neonates, was noticed in neonate's lymphocytes when tocolytic therapy was over a month. Ritodrine revealed a cytoprotective action against smoking when the two factors were combined, but the synergistic action of ritodrine with smoking increased genotoxicity, cytostaticity and cytotoxicity of neonates after long administration (1-3 months). CONCLUSIONS: The time-depended genotoxic, cytostatic and cytotoxic action of ritodrine alone or in combination with smoking suggests that its administration should not exceed the time period of a month.
[Mh] Termos MeSH primário: Fibroblastos/efeitos dos fármacos
Linfócitos/efeitos dos fármacos
Trabalho de Parto Prematuro/tratamento farmacológico
Nascimento Prematuro/tratamento farmacológico
Ritodrina/efeitos adversos
Fumar/efeitos adversos
Tocolíticos/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Análise de Variância
Estudos de Casos e Controles
Proliferação Celular
Feminino
Idade Gestacional
Seres Humanos
Recém-Nascido
Masculino
Índice Mitótico
Gravidez
Nascimento Prematuro/prevenção & controle
Ritodrina/administração & dosagem
Troca de Cromátide Irmã
Fatores de Tempo
Tocolíticos/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Tocolytic Agents); I0Q6O6740J (Ritodrine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160109
[St] Status:MEDLINE
[do] DOI:10.3109/14767058.2015.1135121


  8 / 935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26138627
[Au] Autor:Kinoshita H; Katoh Y; Yoshino H; Sumie Y; Tanaka M; Fujiwara Y
[Ad] Endereço:Department of Anesthesiology, Aichi Medical University School of Medicine, Nagakute, Japan. Electronic address: hkinoshi@aichi-med-u.ac.jp.
[Ti] Título:Acute hypokalemia induced by ritodrine and rebound hyperkalemia in a parturient undergoing a cesarean section.
[So] Source:J Clin Anesth;28:78-9, 2016 Feb.
[Is] ISSN:1873-4529
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Cesárea
Hiperpotassemia/induzido quimicamente
Hipopotassemia/induzido quimicamente
Ritodrina/efeitos adversos
Tocolíticos/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Anestesia Obstétrica
Índice de Apgar
Feminino
Sofrimento Fetal/cirurgia
Seres Humanos
Recém-Nascido
Gravidez
[Pt] Tipo de publicação:CASE REPORTS; LETTER; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Tocolytic Agents); I0Q6O6740J (Ritodrine)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150704
[St] Status:MEDLINE


  9 / 935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:26645888
[Au] Autor:Yamasmit W; Chaithongwongwatthana S; Tolosa JE; Limpongsanurak S; Pereira L; Lumbiganon P
[Ad] Endereço:Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Samsen Road, Dusit, Bangkok, Thailand, 10300.
[Ti] Título:Prophylactic oral betamimetics for reducing preterm birth in women with a twin pregnancy.
[So] Source:Cochrane Database Syst Rev;(12):CD004733, 2015 Dec 08.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Twin pregnancies are associated with a high risk of neonatal mortality and morbidity due to an increased rate of preterm birth. Betamimetics can decrease contraction frequency or delay preterm birth in singleton pregnancies by 24 to 48 hours. The efficacy of oral betamimetics in women with a twin pregnancy is unproven. OBJECTIVES: To assess the effectiveness of prophylactic oral betamimetics for the prevention of preterm labour and birth for women with twin pregnancies. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group Trials Register (21 September 2015), MEDLINE (January 1966 to 31 July 2015), EMBASE (January 1985 to 31 July 2015) and reference lists of retrieved studies. SELECTION CRITERIA: Randomised controlled trials in twin pregnancies comparing oral betamimetics with placebo or any intervention with the specific aim of preventing preterm birth. Quasi-randomised controlled trials, cluster-randomised trials and cross-over trials were not eligible for inclusion. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. Two authors assessed the quality of the evidence using the GRADE approach. MAIN RESULTS: Overall, the quality of evidence is low for the primary outcomes. All of the included trials had small numbers of participants and few events. Preterm birth, the most important primary outcome, had wide confidence intervals crossing the line of no effect.Six trials (374 twin pregnancies) were included, but only five trials (344 twin pregnancies) contributed data. All trials compared oral betamimetics with placebo.Betamimetics reduced the incidence of preterm labour (two trials, 194 twin pregnancies, risk ratio (RR) 0.37; 95% confidence interval (CI) 0.17 to 0.78; low quality evidence). However, betamimetics did not reduce prelabour rupture of membranes (one trial, 144 twin pregnancies, RR 1.42; 95% CI 0.42 to 4.82; low quality evidence), preterm birth less than 37 weeks' gestation (four trials, 276 twin pregnancies, RR 0.85; 95% CI 0.65 to 1.10; low quality evidence), or less than 34 weeks' gestation (one trial, 144 twin pregnancies, RR 0.47; 95% CI 0.15 to 1.50; low quality evidence). Mean neonatal birthweight in the betamimetic group was significantly higher than in the placebo group (three trials, 478 neonates, mean difference 111.22 g; 95% CI 22.21 to 200.24). Nevertheless, there was no evidence of an effect of betamimetics in reduction of low birthweight (two trials, 366 neonates, average RR 1.19; 95% CI 0.77 to 1.85, random-effects), or small-for-gestational age neonates (two trials, 178 neonates, average RR 0.90; 95% CI 0.41 to 1.99, random-effects). Two trials showed that betamimetics significantly reduced the incidence of respiratory distress syndrome (388 neonates, RR 0.30; 95% CI 0.12 to 0.77), but the difference was not significant when the analysis was adjusted to account for the non-independence of twins (194 twins, RR 0.35; 95% CI 0.11 to 1.16). Three trials showed no evidence of an effect of betamimetics in reducing neonatal mortality, either with the unadjusted analysis, assuming twins are completely independent of each other (452 neonates, average RR 0.90; 95% CI 0.15 to 5.37, random-effects), or in the adjusted analysis, assuming non-independence of twins (226 twins, average RR 0.74; 95% CI 0.23 to 2.38, random-effects). A maternal death was reported in one trial without a significant difference between the groups (144 women, RR 2.84; 95% CI 0.12 to 68.57). AUTHORS' CONCLUSIONS: There is insufficient evidence to support or refute the use of prophylactic oral betamimetics for preventing preterm birth in women with a twin pregnancy.
[Mh] Termos MeSH primário: Agonistas Adrenérgicos beta/administração & dosagem
Gravidez de Gêmeos
Nascimento Prematuro/prevenção & controle
Tocolíticos/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Albuterol/administração & dosagem
Feminino
Fenoterol/administração & dosagem
Ruptura Prematura de Membranas Fetais/prevenção & controle
Idade Gestacional
Seres Humanos
Isoxsuprina/administração & dosagem
Gravidez
Ensaios Clínicos Controlados Aleatórios como Assunto
Ritodrina/administração & dosagem
Terbutalina/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.; REVIEW
[Nm] Nome de substância:
0 (Adrenergic beta-Agonists); 0 (Tocolytic Agents); 22M9P70OQ9 (Fenoterol); I0Q6O6740J (Ritodrine); N8ONU3L3PG (Terbutaline); QF8SVZ843E (Albuterol); R15UI3245N (Isoxsuprine)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:160602
[Lr] Data última revisão:
160602
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151210
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD004733.pub4


  10 / 935 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26424315
[Au] Autor:Ishikawa K; Ohsaka H; Omori K; Obinata M; Mishima K; Oode Y; Yanagawa Y
[Ad] Endereço:Department of Acute Critical Care Medicine, Shizuoka Hospital, Juntendo University, Japan.
[Ti] Título:Pregnant Woman Bitten by a Japanese Mamushi (Gloydius blomhoffii).
[So] Source:Intern Med;54(19):2517-20, 2015.
[Is] ISSN:1349-7235
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:We herein report the fourth case of a pregnant woman bitten by a mamushi. A 33-year-old pregnant woman in the 25th week of gestation was bitten by a mamushi. Her vital signs were stable; however, biochemical analyses of the blood showed mild deterioration of anemia and hypoproteinemia. The effects of envenomation were limited to the extremities, the administration of supportive therapy without antivenom fortunately resulted in a favorable outcome. As there are differences in the maternal medical condition and weeks of gestation, further research is needed to clarify the optimal management strategy for administering antivenom in pregnancy.
[Mh] Termos MeSH primário: Anemia/etiologia
Hipoproteinemia/etiologia
Complicações na Gravidez
Mordeduras de Serpentes/complicações
Viperidae
[Mh] Termos MeSH secundário: Adulto
Anemia/tratamento farmacológico
Anemia/imunologia
Animais
Antibacterianos/administração & dosagem
Anti-Inflamatórios não Esteroides/administração & dosagem
Antivenenos
Benzilisoquinolinas/administração & dosagem
Esquema de Medicação
Feminino
Seres Humanos
Hipoproteinemia/tratamento farmacológico
Hipoproteinemia/imunologia
Japão/epidemiologia
Gravidez
Ritodrina/administração & dosagem
Mordeduras de Serpentes/tratamento farmacológico
Mordeduras de Serpentes/imunologia
Toxoide Tetânico/administração & dosagem
Tocolíticos/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Antivenins); 0 (Benzylisoquinolines); 0 (Tetanus Toxoid); 0 (Tocolytic Agents); 7592YJ0J6T (cepharanthine); I0Q6O6740J (Ritodrine)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:151001
[Lr] Data última revisão:
151001
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151002
[St] Status:MEDLINE
[do] DOI:10.2169/internalmedicine.54.4708



página 1 de 94 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde